CRISPR Goodwill and Intangible Assets Trend from 2010 to 2022

CRSP
 Stock
  

USD 63.28  3.62  5.41%   

CRISPR Therapeutics Goodwill and Intangible Assets yearly trend continues to be very stable with very little volatility. Goodwill and Intangible Assets are likely to grow to about 128.3 K this year. During the period from 2010 to 2022, CRISPR Therapeutics Goodwill and Intangible Assets quarterly data regression pattern had range of 384,000 and median of  399,000. CRISPR Therapeutics Operating Income is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Operating Income of 373.53 Million. As of 28th of June 2022, Revenues is likely to grow to about 987.2 M, while Weighted Average Shares is likely to drop about 62.1 M.
  
Refresh
Check CRISPR Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CRISPR main balance sheet or income statement drivers, such as Consolidated Income of 407.5 M, Earning Before Interest and Taxes EBIT of 409.5 M or Gross Profit of 987.2 M, as well as many exotic indicators such as Asset Turnover of 0.38, Book Value per Share of 34.09 or Current Ratio of 19.3. CRISPR financial statements analysis is a perfect complement when working with CRISPR Therapeutics Valuation or Volatility modules. It can also supplement various CRISPR Therapeutics Technical models. Continue to the analysis of CRISPR Therapeutics Correlation against competitors.

CRISPR Therapeutics Quarterly Goodwill and Intangible Assets

112,000

Share

CRISPR Goodwill and Intangible Assets Breakdown

Showing smoothed Goodwill and Intangible Assets of CRISPR Therapeutics AG with missing and latest data points interpolated. A component of Total Assets representing the carrying amounts of all intangible assets and goodwill as of the balance sheet date; net of accumulated amortization and impairment charges.CRISPR Therapeutics' Goodwill and Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CRISPR Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Goodwill and Intangible Assets10 Years Trend
Decreasing
Slightly volatile
 Goodwill and Intangible Assets 
Share
      Timeline 

CRISPR Goodwill and Intangible Assets Regression Statistics

Arithmetic Mean 361,484
Geometric Mean 323,050
Coefficient Of Variation 42.53
Mean Deviation 133,479
Median 399,000
Standard Deviation 153,723
Range 384,000
R-Value(0.96)
R-Squared 0.92
Significance 0.00000022
Slope(37,870)

CRISPR Goodwill and Intangible Assets History

2015454 K
2016399 K
2017344 K
2018289 K
2019235 K
2020180 K
2021125 K
2022128.3 K

About CRISPR Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include CRISPR Therapeutics income statement, its balance sheet, and the statement of cash flows. CRISPR Therapeutics investors use historical funamental indicators, such as CRISPR Therapeutics's Goodwill and Intangible Assets, to determine how well the company is positioned to perform in the future. Although CRISPR Therapeutics investors may use each financial statement separately, they are all related. The changes in CRISPR Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CRISPR Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on CRISPR Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in CRISPR Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Goodwill and Intangible Assets125 K128.3 K
Average Assets2.6 B2.8 B
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

CRISPR Therapeutics Investors Sentiment

The influence of CRISPR Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in CRISPR. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CRISPR Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CRISPR Therapeutics' short interest history, or implied volatility extrapolated from CRISPR Therapeutics options trading.

Current Sentiment - CRSP

CRISPR Therapeutics Investor Sentiment

Most of Macroaxis users are currently bullish on CRISPR Therapeutics AG. What is your opinion about investing in CRISPR Therapeutics AG? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

CRISPR Therapeutics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of CRISPR Therapeutics Correlation against competitors. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Fund Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.